The agreement with the Rwandan government, which initially covers about 60 products, is a first step toward a sustainable ...

Sandoz has signed a direct manufacturing and supply agreement with the government of Rwanda to promote the stable provision ...

Ever wondered if Sandoz Group stock could be a hidden value play, or if you're just jumping in after the most exciting moves? Let's find out what might actually be under the hood. After a rocky 2.4% ...

Sandoz is doubling down on its commitment to Slovenia in its globe-trotting biosimilar growth quest. The Novartis generics unit is plugging $90 million into a new biosimilar technical development ...

Right on the heels of Pfizer’s Accuretic recall, nitrosamine impurities have forced another major drugmaker to pull certain meds from U.S. shelves. Novartis’ Sandoz is recalling 13 lots of oral ...

Sandoz bought the Cimerli (ranibizumab-eqrn) business from Coherus Biosciences, the companies announced Monday morning. In January, Sandoz and Coherus entered into an agreement on a $170 million cash ...

(Reuters) -Sandoz shares dipped on their market debut on Wednesday after the generic and biosimilar drugmaker was valued at a lower-than-expected 10.3 billion Swiss francs ($11.2 billion) in its ...

Sandoz is celebrating the 20th anniversary of European regulatory approval for Omnitrope (somatropin) as the world’s first-ever biosimilar medicine. Omnitrope was approved by th ...

If you are wondering whether Sandoz Group is still reasonably priced after its strong run or if the value case has already ...

In an unusual move, Sandoz is no longer cooperating with a U.K. industry trade group following a dispute over allegations that the company inappropriately marketed a biosimilar medicine. At issue was ...